IDEAS home Printed from https://ideas.repec.org/
MyIDEAS: Login

Citations for "Pharmaceuticals and the Developing World"

by Michael Kremer

For a complete description of this item, click here. For a RSS feed for citations of this item, click here.
as in new window

  1. Petra Moser & Alessandra Voena, 2009. "Compulsory Licensing - Evidence from the Trading with the Enemy Act," NBER Working Papers 15598, National Bureau of Economic Research, Inc.
  2. Jeffrey Clemens, 2012. "The Effect of U.S. Health Insurance Expansions on Medical Innovation," Discussion Papers 11-016, Stanford Institute for Economic Policy Research.
  3. David M. Cutler & Angus S. Deaton & Adriana Lleras-Muney, 2006. "The Determinants of Mortality," NBER Working Papers 11963, National Bureau of Economic Research, Inc.
  4. Chris Papageorgiou & Petia Stoytcheva, . "What Do We Know About the Impact of AIDS on Cross-Country Income So Far?," Departmental Working Papers 2005-01, Department of Economics, Louisiana State University.
  5. Reto Foellmi und Josef Zweimüller, . "Inequality and Economic Growth - European Versus U.S. Experiences," IEW - Working Papers 158, Institute for Empirical Research in Economics - University of Zurich.
  6. Petra Moser, 2012. "Patent Laws and Innovation: Evidence from Economic History," NBER Working Papers 18631, National Bureau of Economic Research, Inc.
  7. Padmashree Gehl Sampath, 2010. "Economic Aspects of Access to Medicines after 2005: Product Patent Protection and Emerging Firm Strategies in the Indian Pharmaceutical Industry," Working Papers id:3336, eSocialSciences.
  8. Gino Gancia, 2003. "Globalization, Divergence and Stagnation," Working Papers 198, Barcelona Graduate School of Economics.
  9. Entorf, Horst & Fegert, Jörg & Kölch, Michael, 2004. "Children in Need of Medical Innovation," ZEW Discussion Papers 04-49, ZEW - Zentrum für Europäische Wirtschaftsforschung / Center for European Economic Research.
  10. Kessing, Sebastian & Nuscheler, Robert, 2003. "Monopoly pricing with negative network effects: the case of vaccines
    [Monopolpreisbildung mit negativen Netzwerkeffekten am Beispiel von Impfstoffen]
    ," Discussion Papers, Research Unit: Market Processes and Governance SP II 2003-06, Social Science Research Center Berlin (WZB).
  11. Mueller-Langer, Frank, 2013. "Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?," Health Economics, Policy and Law, Cambridge University Press, vol. 8(02), pages 185-208, April.
  12. Margaret E. Blume-Kohout & Neeraj Sood, 2008. "The Impact of Medicare Part D on Pharmaceutical R&D," NBER Working Papers 13857, National Bureau of Economic Research, Inc.
  13. Y. Wang, 2006. "Price competition in the chinese pharmaceutical market," International Journal of Health Care Finance and Economics, Springer, vol. 6(2), pages 119-129, June.
  14. Shandre M. Thangavelu & Sanja Samirana Pattnayak, 2006. "Linkages and Spillovers from Foreign Ownership in the Indian Pharmaceutical Firms," SCAPE Policy Research Working Paper Series 0605, National University of Singapore, Department of Economics, SCAPE.
  15. Chris Papageorgiou & Andreas Savvides & Marios Zachariadis, . "International Medical R&D Spillovers," Departmental Working Papers 2004-03, Department of Economics, Louisiana State University.
  16. David M. Cutler & Ellen Meara & Seth Richards, 2009. "Induced Innovation and Social Inequality: Evidence from Infant Medical Care," NBER Working Papers 15316, National Bureau of Economic Research, Inc.
  17. repec:dgr:uvatin:20050062 is not listed on IDEAS
  18. Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," The Quarterly Journal of Economics, MIT Press, vol. 119(3), pages 1049-1090, August.
  19. Papageorgiou, Chris & Savvides, Andreas & Zachariadis, Marios, 2007. "International medical technology diffusion," Journal of International Economics, Elsevier, vol. 72(2), pages 409-427, July.
  20. Tomas Philipson & Stephane Mechoulan & Anupam Jena, 2006. "Health Care, Technological Change, and Altruistic Consumption Externalities," NBER Working Papers 11930, National Bureau of Economic Research, Inc.
  21. Margaret K. Kyle & Anita M. McGahan, 2012. "Investments in Pharmaceuticals Before and After TRIPS," The Review of Economics and Statistics, MIT Press, vol. 94(4), pages 1157-1172, November.
  22. Bastian Rake, 2013. "Determinants of Pharmaceutical Innovation: The Role of Technological Opportunities Revisited," DRUID Working Papers 13-03, DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies.
  23. repec:dgr:uvatin:2005062 is not listed on IDEAS
  24. Clive Bell & Carsten Fink, 2005. "Aide et santé," Revue d’économie du développement, De Boeck Université, vol. 19(2), pages 135-166.
  25. Harsha Thirumurthy & Joshua Graff Zivin & Markus Goldstein, 2006. "The Economic Impact of AIDS Treatment: Labor Supply in Western Kenya," Working Papers 947, Economic Growth Center, Yale University.
  26. Paul Grootendorst, 2009. "How should we support pharmaceutical innovation?," Social and Economic Dimensions of an Aging Population Research Papers 246, McMaster University.
  27. Saradindu Bhaduri & Thomas Brenner, 2013. "Examining the determinants of drug launch delay in pre-TRIPS India," The European Journal of Health Economics, Springer, vol. 14(5), pages 761-773, October.
  28. Shandre M. Thangavelu & Sanja Samirana Pattnayak, 2006. "Linkages and Spillovers from Foreign Ownership in the Indian Pharmaceutical Firms," Development Economics Working Papers 22579, East Asian Bureau of Economic Research.
  29. David Popp, 2012. "The Role of Technological Change in Green Growth," NBER Working Papers 18506, National Bureau of Economic Research, Inc.
  30. Laura Magazzini & Fabio Pammolli & Massimo Riccaboni, 2009. "Nuove politiche per l'innovazione nel settore delle scienze della vita," Working Papers 03-2009, Competitività Regole Mecati (CERM).
  31. Patricia M. Danzon & Eric L. Keuffel, 2013. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484 National Bureau of Economic Research, Inc.
  32. Murray, Fiona & Stern, Scott & Campbell, Georgina & MacCormack, Alan, 2012. "Grand Innovation Prizes: A theoretical, normative, and empirical evaluation," Research Policy, Elsevier, vol. 41(10), pages 1779-1792.
  33. Tomas Philipson & Stephane Mechoulan, 2003. "Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets," NBER Working Papers 9598, National Bureau of Economic Research, Inc.
  34. Harsha Thirumurthy & Markus Goldstein & Joshua Graff Zivin, 2005. "The Economic Impact of AIDS Treatment: Labor Supply in Western Kenya," Working Papers id:300, eSocialSciences.
  35. Ghauri, Pervez N. & Rao, P.M., 2009. "Intellectual property, pharmaceutical MNEs and the developing world," Journal of World Business, Elsevier, vol. 44(2), pages 206-215, April.
  36. Ken Tabata & Testuya Shinkai & Satoru Tanaka & Makoto Okamura, 2005. "Parallel Imports, Drag Price Control and Pharmaceutical Innovation," Discussion Paper Series 26, School of Economics, Kwansei Gakuin University, revised Aug 2005.
  37. Md. Nurul Amin & Tetsushi Sonobe, 2013. "The success of the industrial development policy in the pharmaceutical industry in Bangladesh," GRIPS Discussion Papers 13-07, National Graduate Institute for Policy Studies.
  38. Arvate, Paulo & Barbosa, Klenio de Souza & Gambardella, Dante, 2013. "Generic-branded drug competition and the price for pharmaceuticals in procurement auctions," Textos para discussão 333, Escola de Economia de São Paulo, Getulio Vargas Foundation (Brazil).
This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.